Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Exchange Rate Effect: 2022-2025

Historic Exchange Rate Effect for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$501,000.

  • Centessa Pharmaceuticals' Exchange Rate Effect rose 73.69% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $901,000, marking a year-over-year increase of 139.02%. This contributed to the annual value of $1.2 million for FY2024, which is 99.51% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Exchange Rate Effect is -$501,000, which was down 343.36% from -$113,000 recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Exchange Rate Effect high stood at $3.0 million for Q4 2024, and its period low was -$1.9 million during Q3 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Exchange Rate Effect averaged around -$26,273, with its median value being -$113,000 (2025).
  • The largest annual percentage gain for Centessa Pharmaceuticals' Exchange Rate Effect in the last 5 years was 701.59% (2024), contrasted with its biggest fall of 965.45% (2024).
  • Centessa Pharmaceuticals' Exchange Rate Effect (Quarterly) stood at $722,000 in 2022, then plummeted by 169.81% to -$504,000 in 2023, then soared by 701.59% to $3.0 million in 2024, then soared by 73.69% to -$501,000 in 2025.
  • Its Exchange Rate Effect was -$501,000 in Q3 2025, compared to -$113,000 in Q2 2025 and -$1.5 million in Q1 2025.